(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly ADP-ribose polymerase) inhibitor class. The FDA also approved Myriad Genetics’ BRACAnalysis CDx test to determine patients’ BRCA status as a companion diagnostic for determining whether … Continued
When Diane Riche’s mother was diagnosed with ovarian cancer in 2010, Diane turned to the internet for information. Through her research she came to the Alliance’s website, where she learned that ovarian cancer does in fact have symptoms. Diane recalls thinking: “What do you mean ‘Know the symptoms’? There are no symptoms for ovarian cancer!” … Continued
(12/14/14) | In 2014, with your generous support OCRF grantees made significant advances in the fight against ovarian cancer, including: Thank you for supporting our mission to fund scientific research that will lead to more effective identification, treatment, and ultimately a cure for this terrible disease.
(December 10, 2014) OCRF Ann Schreiber Mentored Investigator Award Grantee, Pradeep Chaluvally-Raghavan, Ph.D., and other researchers at The University of Texas MD Anderson Cancer Center believe they may have found a molecule-based approach to halting the destructive nature of a genetic misfire called the 3q26.2 amplicon. The research was funded in part by a grant … Continued
Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. A new study published in the Journal of the National Cancer Institute compared the cost-effectiveness of population-based BRCA testing with the standard FH-based approach in Ashkenazi Jewish (AJ) women. The study found that population-based … Continued
One of the Ovarian Cancer National Alliance’s first Partner Members, the Ovarian Cancer Alliance of California (OCA) parallels the Alliance in many ways. Originally founded in 1998 as a chapter of the National Ovarian Cancer Coalition, the OCA quickly evolved as an organization, focusing more on involvement specifically in the Central Valley area, as Maria … Continued
A special message from OCRF Founder and Chair, Sol Schreiber.
OCRF’s 20th Anniversary Legends Gala, hosted by Harry Connick, Jr., was held on Wednesday, November 5th at The Pierre Hotel in New York City. Honorees included the Janet Burros Memorial Foundation, Chris Salgardo, President of Kiehl’s Since 1851, and Pierce Brosnan. The event also included tributes to the late Liz Tilberis, former OCRF President and … Continued
Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. The approval was based on results from a study that showed Avastin plus chemotherapy reduced the risk of disease worsening or … Continued
The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society. A study found significant improvement in progression-free survival among patients treated with … Continued
Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group. Analysts said oncologists expect the drug to have little or … Continued
Teal Diva’s origins lie in a common need of those affected by ovarian cancer: support. When Shannon Routh was diagnosed with ovarian cancer in 2009, she also discovered that she would be unable to have children, despite her young age. For Shannon this made relating with other survivors difficult, as many of the survivors she … Continued
Get email updates about research news, action alerts, and ways to join the fight.
